R
Robert Kleemann
Researcher at Netherlands Organisation for Applied Scientific Research
Publications - 188
Citations - 13407
Robert Kleemann is an academic researcher from Netherlands Organisation for Applied Scientific Research. The author has contributed to research in topics: Inflammation & Macrophage migration inhibitory factor. The author has an hindex of 56, co-authored 164 publications receiving 11957 citations. Previous affiliations of Robert Kleemann include Leiden University Medical Center & University of Düsseldorf.
Papers
More filters
Journal ArticleDOI
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
Jürgen Bernhagen,Regina M. Krohn,Hongqi Lue,Julia L. Gregory,Alma Zernecke,Rory R. Koenen,Manfred Dewor,Ivan T. Georgiev,Andreas Schober,Lin Leng,Teake Kooistra,Gunter Fingerle-Rowson,Pietro Ghezzi,Robert Kleemann,Shaun R. McColl,Richard Bucala,Michael J. Hickey,Christian Weber +17 more
TL;DR: Targeting MIF in individuals with manifest atherosclerosis can potentially be used to treat this condition and displays chemokine-like functions and acts as a major regulator of inflammatory cell recruitment and atherogenesis.
Journal ArticleDOI
Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD.
Eveline Gart,Everton Souto Lima,Frank H. J. Schuren,Christa de Ruiter,Joline Attema,Lars Verschuren,Jaap Keijer,Kanita Salic,Martine C. Morrison,Robert Kleemann +9 more
TL;DR: A first systematic analysis of microbiota changes in the ileum and colon using multiple diets and investigating both fecal and mucosal samples demonstrates correlations between the microbiota and dysfunctions of gut, adipose tissue, and liver, independent of a specific disease-inducing diet.
Journal ArticleDOI
Cytokines and atherosclerosis: a comprehensive review of studies in mice
TL;DR: This survey summarizes the currently available information from mouse studies on the contribution of a specified group of cytokines expressed in atherosclerotic lesions and concludes that only for a few cytokines there is sufficient consistent data allowing classifying them as typically proatherogenic (IL-1,IL-12, IL-18, MIF, IFN-γ, TNF-α, and M-CSF) or anti-atherogensic ( IL-10).
Journal ArticleDOI
Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1
Robert Kleemann,Angelika Hausser,Georg Geiger,Ralf Mischke,Anke Burger-Kentischer,Oliver Flieger,Franz-Josef Johannes,Thierry Roger,Thierry Calandra,Aphrodite Kapurniotu,Matthias Grell,Matthias Grell,Doris Finkelmeier,Herwig Brunner,Jürgen Bernhagen +14 more
TL;DR: It is concluded that MIF may act broadly to negatively regulate Jab1-controlled pathways and that the MIF–Jab1 interaction may provide a molecular basis for key activities of MIF.
Journal ArticleDOI
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Susanne Zadelaar,Robert Kleemann,Lars Verschuren,Jitske de Vries-van der Weij,José W.A. van der Hoorn,Hans M.G. Princen,Teake Kooistra +6 more
TL;DR: The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches and the choice of a model should take into account the risk factor to be studied and the working spectrum of the compounds tested.